[go: up one dir, main page]

TN2009000033A1 - Derives de pyrazole servant d'inhibiteurs du cytochrome p450 - Google Patents

Derives de pyrazole servant d'inhibiteurs du cytochrome p450

Info

Publication number
TN2009000033A1
TN2009000033A1 TN2009000033A TN2009000033A TN2009000033A1 TN 2009000033 A1 TN2009000033 A1 TN 2009000033A1 TN 2009000033 A TN2009000033 A TN 2009000033A TN 2009000033 A TN2009000033 A TN 2009000033A TN 2009000033 A1 TN2009000033 A1 TN 2009000033A1
Authority
TN
Tunisia
Prior art keywords
cytochrome
inhibitors
pyrazole derivatives
solvates
salts
Prior art date
Application number
TN2009000033A
Other languages
English (en)
Inventor
Simon Paul Planken
Scott Channing Sutton
Rongliang Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TN2009000033A1 publication Critical patent/TN2009000033A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention propose des composés de formule (I) ou leurs sels ou produits de solvatation, des procédés pour leur préparation et des formulations pharmaceutiques les contenant.
TN2009000033A 2006-07-05 2009-01-30 Derives de pyrazole servant d'inhibiteurs du cytochrome p450 TN2009000033A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80659606P 2006-07-05 2006-07-05
US91098807P 2007-04-10 2007-04-10
US94180807P 2007-06-04 2007-06-04
PCT/IB2007/001878 WO2008004096A1 (fr) 2006-07-05 2007-06-25 Dérivés de pyrazole utilisés en tant qu'inhibiteurs du cytochrome p450

Publications (1)

Publication Number Publication Date
TN2009000033A1 true TN2009000033A1 (fr) 2010-08-19

Family

ID=38515807

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000033A TN2009000033A1 (fr) 2006-07-05 2009-01-30 Derives de pyrazole servant d'inhibiteurs du cytochrome p450

Country Status (24)

Country Link
US (1) US7919488B2 (fr)
EP (1) EP2046774A1 (fr)
KR (1) KR20090034958A (fr)
CN (1) CN101511812A (fr)
AP (1) AP2009004763A0 (fr)
AR (1) AR062154A1 (fr)
AU (1) AU2007270814B2 (fr)
CA (1) CA2660031A1 (fr)
CO (1) CO6150178A2 (fr)
CR (1) CR10573A (fr)
EA (1) EA200900135A1 (fr)
GT (1) GT200700053A (fr)
IL (1) IL196490A0 (fr)
MA (1) MA30629B1 (fr)
MX (1) MX2009000482A (fr)
NO (1) NO20090346L (fr)
NZ (1) NZ574207A (fr)
PE (1) PE20080998A1 (fr)
RS (1) RS20090036A (fr)
TN (1) TN2009000033A1 (fr)
TW (1) TWI334867B (fr)
UY (1) UY30460A1 (fr)
WO (1) WO2008004096A1 (fr)
ZA (1) ZA200900478B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2099454A4 (fr) * 2006-11-17 2010-11-10 Abbott Lab Aminopyrrolidines utilisés en tant qu'antagonistes du récepteur de la chimiokine
WO2008112022A1 (fr) * 2007-03-13 2008-09-18 Arete Therapeutics, Inc. Inhibiteurs de l'époxyde hydrolase soluble
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
EP2268611A2 (fr) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Antagonistes d aminoalkylphényle de récepteurs de prostaglandine d<sb>2</sb>
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
WO2010057118A2 (fr) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
US8748442B2 (en) 2010-06-30 2014-06-10 Ironwood Pharmaceuticals, Inc. sGC stimulators
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
EP2797915B1 (fr) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. Dérivés de 2-bénzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole en tant que stimulateurs de la cyclase de guanylate soluble (sGC) pour le traitement de la hypertension ou de l'insuffisance cardiaque
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
WO2014000178A1 (fr) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Dérivés de sulfamide et leurs méthodes d'utilisation permettant d'améliorer la pharmacocinétique d'un médicament
WO2014194519A1 (fr) * 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Dérivés imidazole et leurs procédés d'utilisation pour l'amélioration des propriétés pharmacocinétiques d'un médicament
WO2015070367A1 (fr) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Dérivés d'imidazole et de triazole liés à la pipéridine ou la pipérazine et leurs procédés d'utilisation pour améliorer la pharmacocinétique d'un médicament
WO2015070366A1 (fr) * 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Dérivés d'imidazole et de triazole liés à aryle et leurs procédés d'utilisation pour améliorer la pharmacocinétique d'un médicament
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0024795D0 (en) 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
BR0208561A (pt) * 2001-04-05 2004-03-30 Torrent Pharmaceuticals Ltd Compostos heterocìclicos para complicações vasculares diabéticas e relacionadas ao envelhecimento
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7662844B2 (en) * 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
HRP20100272T2 (hr) 2005-09-23 2010-07-31 Pfizer Products Incorporated Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4)

Also Published As

Publication number Publication date
AU2007270814A1 (en) 2008-01-10
TW200811159A (en) 2008-03-01
WO2008004096A1 (fr) 2008-01-10
PE20080998A1 (es) 2008-08-15
GT200700053A (es) 2009-08-03
CA2660031A1 (fr) 2008-01-10
CN101511812A (zh) 2009-08-19
EP2046774A1 (fr) 2009-04-15
IL196490A0 (en) 2011-07-31
US7919488B2 (en) 2011-04-05
RS20090036A (sr) 2010-06-30
TWI334867B (en) 2010-12-21
MX2009000482A (es) 2009-01-27
AR062154A1 (es) 2008-10-22
CO6150178A2 (es) 2010-04-20
UY30460A1 (es) 2008-02-29
AP2009004763A0 (en) 2009-02-28
KR20090034958A (ko) 2009-04-08
NZ574207A (en) 2010-10-29
EA200900135A1 (ru) 2009-06-30
NO20090346L (no) 2009-02-19
US20080021011A1 (en) 2008-01-24
AU2007270814B2 (en) 2011-07-14
ZA200900478B (en) 2010-04-28
CR10573A (es) 2009-02-12
MA30629B1 (fr) 2009-08-03

Similar Documents

Publication Publication Date Title
TN2009000033A1 (fr) Derives de pyrazole servant d&#39;inhibiteurs du cytochrome p450
MA29791B1 (fr) Composes therapeutiques.
MA31419B1 (fr) Derives de pyridine
TNSN07022A1 (fr) Derives de pyridine
MA32965B1 (fr) Derives de sulfonamides
MA29926B1 (fr) Derives de pyrazine
MY148634A (en) Pyridazinone derivatives
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu&#39;antagonistes de bradykinine
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA29160B1 (fr) Derives de triazole substitues, servant d&#39;antagonistes d&#39;ocytocine
MA30487B1 (fr) Nouveaux composes heterocycliques
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d&#39;inhibiteurs de PDE 2
MA31754B1 (fr) Cis-imidazolines chirales
MA29839B1 (fr) Derives de carboxamides servant d&#39;antagonistes des recepteurs muscariniques
WO2007087548A3 (fr) Composés chimiques
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
MA29647B1 (fr) Agonistes du recepteur de la niacine, compositions contenant de tels composes et procedes de traitement
MA34047B1 (fr) Polymorphes et solvates de chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
TNSN05202A1 (fr) Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant
WO2007073303A3 (fr) Nouveaux composes iii
WO2008038092A3 (fr) Pipéridinophényloxazolidinones substituées